3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
3
Neoplasms
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Testicular Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Neuroendocrine Tumors
2
Neoplasms, Unknown Primary
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Adrenal Gland Neoplasms
2
Vaginal Neoplasms
1
Uterine Neoplasms
1
Thymus Neoplasms
1
Solitary Fibrous Tumors
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Penile Neoplasms
1
Pancreatic Ductal Adenocarcinoma (PDAC)
1
Hematologic Neoplasms
1
Colorectal Neoplasms
1
Interventions
folfirinox
1
Oxaliplatin
1
Neoadjuvant Therapy
1
Leucovorin
1
Irinotecan
1
FAPI-46
1
Endosonography
1
Blood Specimen Collection
1
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pancreatic Ductal Adenocarcinoma (PDAC)
×
FAPI-46
×
Clear all
NCT06659705
2026-04-15
INDIGO-FAPI
Institut Curie
Phase 2
Recruiting
35 enrolled